AETHLON MEDICAL INC (AEMD)
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Aethlon Medical, Inc.
| Form | Description | Links | |
|---|---|---|---|
| 4 | |||
| 4 | |||
| 4/A | |||
| 4 | |||
| 4 | |||
| 4 | |||
| 13G | |||
| 8-K | |||
| 8-K/A | |||
| 8-K | |||
| 425 | |||
| 8-K | |||
| 8-K | |||
| DEFA14A | |||
| DEF 14A | |||
| 8-K | |||
| PRE 14A | |||
| 10-Q | |||
| 8-K | |||
| 13G/A | |||
| 8-K | |||
| 8-K | |||
| 424B3 | |||
| EFFECT | |||
| 4 |
1-25 of 1,050 filings
Recent SEC filings with analysis
- 8-KAethlon Medical held its virtual Annual Meeting of Stockholders on October 1, 2026, with approximately 56.21% of its 711,136 outstanding shares represented,…
- 8-KAethlon Medical entered into a merger agreement with North Immunology on September 17, 2026 under which two Aethlon merger subsidiaries will merge with North…
- 8-KOn September 11, 2026, Aethlon Medical amended the employment agreements of CEO/CFO James B.